[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Weizmann Institute of Science\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":163},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,37,58,80,100,121,143],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":4},"100642358","replacing-bone-marrow-diagnostics-with-peripheral-blood-analysis-in-mpn-patients-100642358",false,"NCT07648433","Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in MPN Patients","Development of a Peripheral Blood Assay to Replace Bone Marrow Biopsy in Myeloproliferative Neoplasms- a Multi-center Observational Study","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Confirmed MPN diagnosis, based on the WHO criteria (Barbui 2018), which includes:\n\n   Polycythemia Vera (PV) Criteria:\n   * Elevated hemoglobin (\\>16.5 g\u002FdL for men, \\>16.0 g\u002FdL for women), hematocrit (\\>49% for men, \\>48% for women), or increased red cell mass\n   * Bone marrow biopsy showing hypercellularity with trilineage growth (panmyelosis)\n   * Presence of JAK2 mutation (V617F or exon 12)\n\n   Essential Thrombocythemia (ET) Criteria:\n   * Platelet count ≥450 ×10⁹\u002FL\n   * Bone marrow biopsy showing proliferation mainly of the megakaryocyte lineage\n   * Not meeting WHO criteria (Alaggio et al., 2022) for other myeloid neoplasms (such as CML, PV, PMF, MDS).\n   * Presence of JAK2, CALR, or MPL mutation Primary Myelofibrosis (PMF) Criteria\n   * Megakaryocytic proliferation and atypia, with or without reticulin fibrosis, and increased marrow cellularity (for prefibrotic\u002Fearly PMF) or significant reticulin\u002Fcollagen fibrosis (for overt PMF)\n   * Not meeting criteria for other myeloid neoplasms\n   * Presence of JAK2, CALR, or MPL mutation, or in their absence, another clonal marker\n3. Patients who are referred for a bone marrow biopsy due to a suspected diagnosis of MPN\n\nExclusion Criteria:\n\n1. Patients diagnosed with MPN receiving therapy\n2. Patients who have undergone a bone marrow transplant","ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","OBSERVATIONAL","This observational, multi-center study aims to collect data to develop a novel, minimally invasive diagnostic tool for myeloproliferative neoplasms (MPN) based on peripheral blood (PB) profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA sequencing (scRNA-seq). Current diagnostic practice relies on bone marrow (BM) biopsy, procedures that is invasive, technically demanding, and may be inconclusive in early or prefibrotic disease stages.\n\nOur prior work established a reference atlas of healthy cHSPC subtypes and a computational pipeline capable of identifying disease-specific transcriptional changes by quantifying deviations from this reference. This study will assess whether PB-based genomic profiling can accurately distinguish MPN from non-clonal cytoses, including secondary erythrocytosis or thrombocytosis.\n\nPatients referred for bone marrow biopsy due to suspected myeloproliferative neoplasm (MPN) will undergo PB collection for genomic profiling. The study's primary objective is to develop a PB-based test by comparing the developed test diagnoses to the conventional BM-based diagnostics. Secondary objectives include evaluating its potential for MPN subtype classification, risk stratification, as well as assessing its ability to reduce the need for BM biopsies.",[24],"Myeloproliferative Neoplasm","NOT_YET_RECRUITING","2026-06-09",{"date":28,"type":29},"2026-06-15","ACTUAL",{"date":31,"type":20},"2026-06",{"date":33,"type":20},"2032-06",{"name":35,"class":36},"Weizmann Institute of Science","OTHER",{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":4,"eligibilityCriteria":42,"healthyVolunteers":43,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":44,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":46,"conditions":47,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":50,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":57},"100554110","decoding-the-clinical-impact-of-host-and-microbial-intestinal-proteomic-landscape-in-crohns-disease-100554110","NCT06494826","Decoding the Clinical Impact of Host and Microbial Intestinal Proteomic Landscape in Crohn's Disease","Inclusion criteria - CD study group:\n\n* Age ≥ 18\n* Candidates for a medically-indicated, diagnostic colonoscopy due to suspected new-onset CD.\n* Naïve to any medical or nutritional intervention.\n\nInclusion criteria - healthy controls:\n\n• Age- and gender-matched patients to the CD group, admitted for non-specific GI complaints (such as changes in bowel movements, bloating, abdominal pain) or routine screening for colorectal cancer as part of primary prevention per clinical guidelines.\n\nExclusion Criteria - both groups:\n\n* Established diagnosis of inflammatory bowel disease (IBD) with prior treatment.\n* Chronic gastro-intestinal disorder (e.g. celiac disease, eosinophilic esophagitis, collagenous gastritis, autoimmune gastritis, etc.).\n* Type 1 or type 2 diabetes mellitus.\n* Past or present history of malignancy.\n* BMI \\> 30 (kg\u002Fm2)\n* Use of systemic antibiotics or probiotics 2 months prior to enrolment.\n* Use of steroids 2 months prior to enrolment (not including a short course of topical steroidal therapy).\n* Any previous major gastric or intestinal surgery.\n* Suspected or proven extensive involvement of non-ileal small intestine or colon, or significant perianal disease.\n* Significantly stricturing or penetrating (fistulizing) disease at presentation.\n* Chronic treatment with any oral\u002Fsystemic immunosuppressive or anti-inflammatory drugs (e.g. steroids, 5-aminosalicylic acid, immunomodulators, biologics, etc.). Patients receiving these drugs as inhalers\u002Fcreams\u002Fointments should not be excluded from the study.\n* Primary immunodeficiency.\n* Pregnancy or breastfeeding in the last 6 months.\n* Serious medical conditions that may alter the gut microbiome composition, based on investigators judgement (for example primary immunodeficiency, autoimmune disorder, or rheumatologic disease).",true,{"count":45,"type":20},40,"In this study, the investigators will explore our protein-based platform assessing commensals potentially contributing to features of CD, while assessing the global composition and abundance of AMPs expressed in the GI tract under specific CD-relevant clinical contexts. This would enable us to (a) identify new commensals contributing to features of CD spectrum and various sub-types; (b) uncover the mechanistic basis of dysbiosis in CD (c) utilize the pipeline to develop new theranostic for disease exacerbation, complication and treatment responses; and (d) potentially enable future exploitation of novel AMP combinations, and their respective antimicrobial capacity to counteract dysbiosis in CD.\n\nUncovering the proteomic manifestations of perturbed host-microbiome communications in CD will eventually enable the development and validation of clinical non-invasive surrogate markers, mechanistically determine causative drivers of CD, and potentially facilitate the development of novel therapeutic interventions.",[48],"Crohn Disease","RECRUITING",{"date":51,"type":29},"2026-06-11",{"date":53,"type":29},"2024-05-01",{"date":55,"type":20},"2029-05",{"name":35,"class":36},1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":43,"sex":16,"minAge":17,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":57},"100513964","the-stool-microbiome-of-treated-and-untreated-ibs-irritable-bowel-syndrome-patients-100513964","NCT05972317","The Stool Microbiome of Treated and Untreated IBS (Irritable Bowel Syndrome) Patients","Generating a Stool Microbiome-based Diagnostic for IBS (Irritable Bowel Syndrome) Patients in Low-FODMAP Treated and Untreated IBS Patients","Inclusion Criteria:\n\n* Male and Female\n* Age - 18-70\n\nExclusion Criteria:\n\n* Consumption of antibiotics 2 months prior to the first day of the experiment.\n* Consumption of probiotic supplements 1 month prior to the first day of the experiment.\n* Type 1 or type 2 diabetes diagnosis.\n* Pregnancy, fertility treatments, breastfeeding 3 months prior to the first day of the study.\n* Chronic disease - to the discretion of the study doctor.\n* Cancer and recent anticancer treatment.\n* Psychiatric disorders - to the discretion of the study doctor.\n* IBD (inflammatory bowel diseases).\n* Alcohol or substance abuse.\n* BMI \\> 35.","70 Years",{"count":67,"type":20},100,"INTERVENTIONAL",[70],"NA","Irritable bowel syndrome (IBS) is considered the most common gastrointestinal disorder in humans, with an estimated global prevalence of 11%-20% of all humans. Alterations in the gut microbiome are at the center of IBS, and microbiome-induced volatile metabolites in response to dietary exposures is believed to drive a downstream impact on susceptible hosts, thereby driving the disease. However, the characteristics and functions of these metabolites remain unknown to date. The two main mechanisms invoking IBS development and flares include 1) an increase in luminal water content due to malabsorption of small molecules and 2) incrementation of colon gas production generated by the fermentation of small molecules by gut bacteria.Yet to date, a person-specific elucidation of the specific small molecules and bacteria driving IBS, and their downstream effects on the human gut epithelium remain unknown.\n\nOver the past years, it became evident that dietary regimes, and their interactions with the intestinal microbiome, are at the center of IBS symptom generation and alleviation. The most widely used dietary intervention is a highly restrictive diet, the low-Fermentable Oligo-saccharides Di-saccharides Mono-saccharides And Polyols (FODMAP) diet, based on avoidance of multiple food items that contain available fermentable molecules.\n\nThe low-FODMAP diet remains an effective line of treatment for IBS patients, yet due to its complexity and unhealthy nature, it remains a last line of treatment and fails to impact the majority of IBS patients.",[73],"Irritable Bowel Syndrome",{"date":51,"type":29},{"date":76,"type":29},"2026-05-11",{"date":78,"type":20},"2029-11",{"name":35,"class":36},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":43,"sex":16,"minAge":17,"maxAge":65,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100464287","improvement-in-glycemic-response-after-bariatric-surgery-100464287","NCT05325736","Improvement in Glycemic Response After Bariatric Surgery","Inclusion Criteria:\n\n* candidates of bariatric surgery or cholecystectomy\n* age 18-70\n* male\u002Ffemale\n\nExclusion Criteria:\n\n* previous bariatric surgery\n* type 1 diabetes\n* antibiotic treatment 3 months prior to the study\n* probiotic treatment 3 months prior to the study\n* chronic disease - gastrointestinal disease, malignancy, psychiatric disorder, endocrinologic disorders\n* any pathologic findings during endoscopy\n* participants who will suffer from a post-operation complication",{"count":87,"type":20},120,"decipher the role of microbiota in glycemic response change after bariatric surgery",[90],"Bariatric Surgery","2026-05-19",{"date":93,"type":29},"2026-05-20",{"date":95,"type":29},"2021-07-01",{"date":97,"type":20},"2029-07-01",{"name":35,"class":36},2,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":99},"100599176","replacing-bone-marrow-diagnostics-with-peripheral-blood-analysis-in-cytopenia-patients-100599176","NCT07081087","Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients","Development of a Peripheral Blood Assay to Replace BM Evaluation in Cytopenia - a Multi-Center Observational Study","Inclusion Criteria:\n\n1. Patients aged 18 and up with suspected\u002Fconfirmed MDS cases referred to BM evaluation either for diagnosis or risk assessment due to cytopenia\n2. Platelets \\\u003C 150 × 10E9\u002FL or\n3. Absolute neutrophil count \\\u003C 1.8 × 10E9\u002FL or\n4. Hemoglobin (Hgb) \\\u003C 13 g\u002FdL (males) and \\\u003C 12 g\u002FdL (female) and\n5. For both sexes, no evidence of Iron, folinic acid, or B12 deficiency\n\nExclusion Criteria:\n\n1. Women who are pregnant\n2. Previous diagnosis of leukemia; AML, MPN, ALL, CLL, MGUS\u002FMM or any other gammopathy\n3. Lymphocytes \\> 5000\u002Ful\n4. Patients who are on disease-related therapy are excluded, unless they are treated with Erythropoietin or Prednisone. See Appendix 2 for the list of excluded treatments.\n5. Patients who have undergone a bone marrow transplant.",{"count":108,"type":20},1500,"This observational, multi-center study aims to collect data in order to develop a novel, minimally invasive diagnostic tool for MDS based on peripheral blood profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA sequencing and DNA sequencing.",[111,112],"Cytopenia","MDS","2026-03-22",{"date":115,"type":29},"2026-03-25",{"date":117,"type":29},"2025-06-01",{"date":119,"type":20},"2028-12",{"name":35,"class":36},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":43,"sex":16,"minAge":17,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":68,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":57},"100568439","the-role-of-microbiome-in-recurrent-obesity-before-and-after-antibioticplacebo-treatment-100568439","NCT06681246","The Role of Microbiome in Recurrent Obesity Before and After Antibiotic\u002FPlacebo Treatment","Inclusion Criteria:\n\n* 28\\\u003CBMI\\\u003C35\n* Age - 18-65\n* Capable of working with a smartphone application\n\nExclusion Criteria:\n\n* Consumption of antibiotics\u002Fprobiotics\u002Foral antifungals 2 months prior to the first day of the experiment.\n* Pregnancy, fertility treatments, breastfeeding women six months prior to enrollment and during the study.\n* Chronic disease, to the discretion of the study team (e.g. AIDS, Cushing syndrome, CKD, acromegaly etc.)\n* Cancer and recent anticancer treatment\n* Psychiatric disorders, to the discretion of the study team.\n* Coagulation disorders\n* IBD (inflammatory bowel diseases)\n* Bariatric surgery.\n* Eating disorders (Anorexia nervosa. Bulimia nervosa. Binge eating disorder, Night eating syndrome).\n* Alcohol or substance abuse\n* Weight loss attempts 6 months prior to the first day of the experiment - using weight loss medication.\n* Drastic changes in nutritional habits six months prior to the first day of the study - to the discretion of the study team.\n* Allergy to penicillin.\n* Life threatening reaction after consumption of cephalosporins.\n* History of CDI\n* Liver disease\n* History of serious unresolved diarrhea in response to antibiotic treatment to the discretion of the study doctor.","65 Years",{"count":129,"type":20},200,[70],"This past century witnessed a significant increase in the prevalence of obesity. Successful weight loss maintenance is defined as losing at least 10% of the initial body weight and maintaining it for at least one year. However, keeping a low body weight is rarely maintained, as 80% of people who lost 10% of their body weight will return to their initial weight within a year. Although there is no agreement as to what contributes to the recurrent weight regain phenomenon (also known as 'weight cycling' or 'yo-yo diet'), it is strongly associated with the risk of developing metabolic risk factors and their complications, including heart disease and all-cause mortality. Altering the gut microbiota is one method to treat disease states associated with gut bacteria. Antibiotics consumption is known to influence host glycemic response through changes induced in microbiome composition and function. Therefore, it may be a possible pathway to jumpstart changes in the gut microbiota.\n\nThis study will determine whether microbiome modulation might be a possible future target against recurrent obesity in humans and whether orally administered antibiotic treatment post-weight loss might be an effective intervention to prevent weight regain.",[133,134],"Obesity","Weight Loss","2026-01-15",{"date":137,"type":29},"2026-01-20",{"date":139,"type":29},"2024-12-11",{"date":141,"type":20},"2027-12",{"name":35,"class":36},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":43,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":57},"100502090","human-phenotype-project-study-protocol-100502090","NCT05817734","Human Phenotype Project Study Protocol","Longitudinal Collection of Observational Clinical and Lifestyle Data","Inclusion Criteria:\n\n* Ages 18+, males and females.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Mentally disabled or in general legally non-competent.\n* Prisoner or soldier. Soldiers: mandatory service only\n* Active cancer\n* Fertility Treatments (current)\n* Hepatitis ( B, C), chronic or acute\n* HIV\n* Liver cirrhosis\n* Dialysis\n* Unstable medical conditions",{"count":151,"type":20},30000,"This is a prospective study aimed at recruiting 30,000 individuals, aged 40-70 years old, and following them longitudinally for 25 years with repeated measurements. The basic follow-up frame will include a visit to the Clinical Test Center (CTC) every two years and a phone interview every other year (on uneven years). Sample collection and biobanking will be performed every two years and online questionnaires will be filled out on an annual basis.\n\nThe primary goals are to study the variation observed across different individuals in disease susceptibility, clinical phenotypes, and therapeutic responses. The study aims at studying the complex interplay and relative contribution of different omics, physiological characteristics and lifestyle on disease pathogenesis and progression and to evaluate how these effects are mediated.",[154],"Adult Disease","2024-07-14",{"date":157,"type":29},"2024-07-16",{"date":159,"type":29},"2018-10-01",{"date":161,"type":20},"2045-12-31",{"name":35,"class":36},""]